SNHG1 and hepatocellular carcinoma: For example, SNHG1 was upregulated in human colorectal cancer tissues, and high SNHG1 expression was associated with shorter OS [29]; SNHG1 contributed to sorafenib resistance by activating the Akt pathway in hepatocellular carcinoma cells [30]; SNHG17 was upregulated in non-small-cell lung cancer (NSCLC), and the knockdown of SNHG17 inhibited the proliferation and migration and promoted the apoptosis of NSCLC cells [31].